Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry PDF full book. Access full book title Relationship between R&D and Financial Performance in Indian Pharmaceutical Industry by Mithun Nandy. Download full books in PDF and EPUB format.
Author: Mithun Nandy
Publisher: Springer Nature
ISBN: 981166921X
Category : Business & Economics
Languages : en
Pages : 224
Get Book Here
Book Description
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach.
Author: Mithun Nandy
Publisher: Springer Nature
ISBN: 981166921X
Category : Business & Economics
Languages : en
Pages : 224
Get Book Here
Book Description
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach.
Author: Keith N. Herist
Publisher: Pharmaceutical Press
ISBN: 085369897X
Category : Business & Economics
Languages : en
Pages : 240
Get Book Here
Book Description
This introductory text covers the basics of accounting and financial management and demonstrates the application of these principles to pharmacy practice. Coverage includes:* the guiding principles of accounting* financial statements, from detailed transactions to summary reports* basics of finance and financial analysis * budgeting and inventory management* pricing goods and services* personal financial management.Case studies, based on realistic examples are used to show how accounting and financial management principles apply to all areas of pharmacy practice. Financial Analysis in Pharmacy Practice is an invaluable resource for graduate students in pharmacy administration and professional pharmacy students, as well as pharmacists in the public and private sectors who wish to be well informed when making financial decisions.Keith N Herist, is Clinical Associate Professor, Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, USA.Brent L Rollins, is Assistant Professor, Pharmacy Administration, Philadelphia College of Osteopathic Medicine, School of Pharmacy, USA.Matthew Perri III, is Professor, Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, USA.
Author: Congressional Budget Office
Publisher: Lulu.com
ISBN: 1304121445
Category : Science
Languages : en
Pages : 65
Get Book Here
Book Description
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030904491X
Category : Medical
Languages : en
Pages : 225
Get Book Here
Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author:
Publisher: DIANE Publishing
ISBN: 9780788104688
Category : Medical
Languages : en
Pages : 380
Get Book Here
Book Description
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Author: David S. Zuckerman
Publisher: Gower Publishing, Ltd.
ISBN: 056608676X
Category : Drugs
Languages : en
Pages : 160
Get Book Here
Book Description
'What gets measured gets fixed' and this is as true of the pharmaceutical industry as any other. The problem is that pharmaceutical businesses are complex. Drug research and development involves extended and expensive processes; defining appropriate metrics for these processes is not easy, yet ineffective or misguided metrics can be more damaging than none at all. David Zuckerman's Pharmaceutical Metrics is an extremely practical guide to selecting a system, selling it to top management, choosing and defining the right metrics for your system, communicating and displaying the results. And because metrics are about how to shape and develop your business, he explores how to deploy them organization-wide and make sure that they are driving business improvement. In order to reflect the needs of different types of pharmaceutical company the author uses four sample companies, throughout the book, to illustrate the principles for 'big pharma', 'micro pharma', a virtual development company and a CRO. This highly practical book provides a step-by-step guide to creating a state-of-the-art, strategy-driven metrics system for pharmaceutical R&D, supported by case studies of the techniques applied and tips for optimizing the system.
Author: William Lazonick
Publisher: Oxford University Press
ISBN: 0192585983
Category : Political Science
Languages : en
Pages : 325
Get Book Here
Book Description
Predatory Value Extraction explains how an ideology of corporate resource allocation known as 'maximizing shareholder value' (MSV) that emerged in the 1980s came to dominate strategic thinking in business schools and corporate boardrooms in the United States. Undermining the social foundations of sustainable prosperity, it resulted in employment instability, income inequity, and slow productivity growth. In explaining what happened to sustainable prosperity, William Lazonick and Jang-Sup Shin focus on the growing imbalance between value creation and value extraction in the U.S. economy, and the corporate-governance institutions that determine this balance in the nation's major business corporations. The imbalance has become so extreme that predatory value extraction is now a central economic activity, to the point at which the U.S. economy as a whole can be aptly described as a value-extracting economy. Balancing the contributions of economic actors to value creation with their power to extract value provides the foundation for stable and equitable economic growth. When certain economic actors are able to assert their power to extract far more value than they contribute to the value-creation process, an imbalance occurs which, when extreme, leads to dire economic, political, and social consequences. This book not only explores these consequences, but also sets out an agenda for restoring sustainable prosperity.
Author: Great Britain: Parliament: House of Commons: Health Committee
Publisher: The Stationery Office
ISBN: 9780215024572
Category : Political Science
Languages : en
Pages : 556
Get Book Here
Book Description
Incorporating HC 1030-i to iii.
Author: Daniel Hoffman
Publisher: Routledge
ISBN: 1000166716
Category : Business & Economics
Languages : en
Pages : 95
Get Book Here
Book Description
The pharmaceutical industry, long thought of as a recession-proof investment, now faces a day of reckoning. The reasons for this impending downfall are not hard to discern. The prices the industry charges for its prescription drugs have escalated at four to five times the cost-of-living increases during the past two decades and have reached a point where 30% of Americans must choose between filling a prescription, paying for housing, and buying food. This has brought about public pressure on governments around the world to control drug prices, yet the world’s twenty largest pharma companies realized 80% of their growth as a result of exorbitant price hikes. Pharma currently enjoys its extraordinary profitability by exploiting the world’s most vulnerable populations. Yet even their ability to increase prices in the face of falling demand does not satisfy their profit demands. The breadth and depth of pharma’s marketing transgressions exceed those of any other industry and have now reached a point where authorities around the world have found it necessary to take legal action against its violations. Drastic change is needed if the pharmaceutical industry can equitably advance the health of the world’s population and regain public esteem. This book illustrates the range and extent of pharma’s violations and addresses the actions that should be implemented in order to make the drug industry a more constructive, less venal part of contemporary society. It will be of interest to researchers, academics, practitioners, and students with an interest in the pharmaceutical industry, healthcare management, regulation, and bioethics.
